Fibrosis and disease progression in hepatitis C
- PMID: 12407576
- DOI: 10.1053/jhep.2002.36993
Fibrosis and disease progression in hepatitis C
Abstract
The progression of fibrosis in chronic hepatitis C determines the ultimate prognosis and thus the need and urgency of therapy. Fibrogenesis is a complex dynamic process, which is mediated by necroinflammation and activation of stellate cells. The liver biopsy remains the gold standard to assess fibrosis. Scoring systems allow a semiquantitative assessment and are useful for cross-sectional and cohort studies and in treatment trials. The rate at which fibrosis progresses varies markedly between patients. The major factors known to be associated with fibrosis progression are older age at infection, male gender, and excessive alcohol consumption. Viral load and genotype do not seem to influence significantly the progression rate. Progression of fibrosis is more rapid in immunocompromised patients. Hepatic steatosis, obesity, and diabetes may also contribute to more rapid progression of fibrosis. There are no tests that reliably predict the rate of progression of fibrosis in an individual patient. High serum alanine aminotransferase (ALT) levels are associated with a higher risk of fibrosis progression, and worsening of fibrosis is uncommon in patients with persistently normal serum aminotransferase levels. Serum markers for fibrosis are not reliable and need to be improved and validated. Liver biopsy provides the most accurate information on the stage of fibrosis and grade of necroinflammation, both of which have prognostic significance. Repeating the liver biopsy, 3 to 5 years after an initial biopsy is the most accurate means of assessing the progression of fibrosis.
Similar articles
-
Predicting progressive hepatic fibrosis stage on subsequent liver biopsy in chronic hepatitis C virus infection.J Viral Hepat. 2005 Jan;12(1):74-80. doi: 10.1111/j.1365-2893.2005.00598.x. J Viral Hepat. 2005. PMID: 15655051
-
Natural history of hepatitis C virus infection: from chronic hepatitis to cirrhosis, to hepatocellular carcinoma.Minerva Gastroenterol Dietol. 2005 Mar;51(1):31-46. Minerva Gastroenterol Dietol. 2005. PMID: 15756144 English, Italian.
-
Fibrosis progression in initially mild chronic hepatitis C.J Viral Hepat. 2006 May;13(5):297-302. doi: 10.1111/j.1365-2893.2005.00683.x. J Viral Hepat. 2006. PMID: 16637859
-
Noninvasive monitoring of patients with chronic hepatitis C.Hepatology. 2002 Nov;36(5 Suppl 1):S57-64. doi: 10.1053/jhep.2002.36800. Hepatology. 2002. PMID: 12407577 Review.
-
Natural history and predictors of disease severity in chronic hepatitis C.J Hepatol. 2006;44(1 Suppl):S19-24. doi: 10.1016/j.jhep.2005.11.009. Epub 2005 Nov 21. J Hepatol. 2006. PMID: 16356583 Review.
Cited by
-
Hepatitis C Infection in the Elderly.Dig Dis Sci. 2015 Nov;60(11):3170-80. doi: 10.1007/s10620-015-3717-6. Epub 2015 May 26. Dig Dis Sci. 2015. PMID: 26008618 Review.
-
Evaluating progression of liver disease from repeat liver biopsies in children with chronic hepatitis C: a retrospective study.Hepatology. 2013 Nov;58(5):1580-6. doi: 10.1002/hep.26519. Epub 2013 Sep 30. Hepatology. 2013. PMID: 23703847 Free PMC article.
-
Relationship between the severity of hepatitis C virus-related liver disease and the presence of Helicobacter species in the liver: a prospective study.World J Gastroenterol. 2006 Dec 7;12(45):7278-84. doi: 10.3748/wjg.v12.i45.7278. World J Gastroenterol. 2006. PMID: 17143941 Free PMC article.
-
Hepatitis C: Problems to extinction and residual hepatic and extrahepatic lesions after sustained virological response.World J Hepatol. 2022 Jan 27;14(1):62-79. doi: 10.4254/wjh.v14.i1.62. World J Hepatol. 2022. PMID: 35126840 Free PMC article. Review.
-
Liver fibrosis is not associated with steatosis but with necroinflammation in French patients with chronic hepatitis C.Gut. 2003 Nov;52(11):1638-43. doi: 10.1136/gut.52.11.1638. Gut. 2003. PMID: 14570735 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical